Status:
WITHDRAWN
Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia
Lead Sponsor:
Rabin Medical Center
Conditions:
Febrile Neutropenia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether short-course antibiotic therapy is safe and effective for the treatment of cancer patients with febrile neutropenia.
Detailed Description
Febrile neutropenia remains a major cause of morbidity in solid cancer patients. There is an unresolved question regarding the appropriate duration of antibiotic treatment for patients with febrile ne...
Eligibility Criteria
Inclusion
- Adults \>18 years providing signed informed consent
- Patients with solid tumors, lymphoma, multiple myeloma or chronic lymphocytic leukemia, regardless of disease status or previous chemotherapy
- Documented febrile neutropenia
- No clinically or microbiologically documented infection after 72 hours
Exclusion
- Previous enrollment in this study
- Concurrent participation in another interventional trial
- Severe sepsis or septic shock
- Acute leukemia, autologous or allogeneic hematopoietic stem-cell transplantation
- Diarrhea suspected by treating physician to be Irinotecan induced
- Any antibiotic treatment for \>48h in the last week before enrollment
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01450241
Start Date
January 1 2012
End Date
January 1 2015
Last Update
June 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center, Beilinson Hospital
Petah Tikvah, Israel